At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 28 enrolled
Drug / intervention
rDEN1delta30 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 19, 2004·Updated Jan 18, 2008
In Brief
A Phase 1 clinical trial evaluating rDEN1delta30 and Placebo for Dengue Fever. Completed, enrolled 28 participants across 1 site.
Detailed Summary
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue Fever
CountriesUnited States
CollaboratorsJohns Hopkins Bloomberg School of Public Health
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2004
Enrollment StartSep 2004
Primary CompletionNov 2005
TodayJul 2026
First PostedAug 19, 2004
Enrollment StartSep 1, 2004
Primary CompletionNov 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 21.9 years ago
Interventions
rDEN1delta30biological
Live attenuated rDEN1delta30 vaccine
Placebobiological
Placebo for rDEN1delta30